

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BRADSHER NEAL C (Last) (First) (Middle) C/O BROADWOOD CAPITAL INC. 724 FIFTH AVENUE, 9TH FLOOR (Street) NEW YORK NY 10019 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol BIOTIME INC [BTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 07/01/2019	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
OPTION TO PURCHASE COMMON SHARES	\$1.03	07/01/2019		A		40,000		07/01/2019 ⁽¹⁾	06/30/2029	COMMON SHARES	40,000	\$0 ⁽²⁾	40,000	D	
OPTION TO PURCHASE COMMON SHARES	\$2.06							06/30/2019 ⁽³⁾	06/30/2023	COMMON SHARES	49,440 ⁽⁴⁾		49,440 ⁽⁴⁾	D	
OPTION TO PURCHASE COMMON SHARES	\$3.15							07/03/2018 ⁽³⁾	06/30/2022	COMMON SHARES	24,720 ⁽⁵⁾		24,720 ⁽⁵⁾	D	
OPTION TO PURCHASE COMMON SHARES	\$2.72							07/03/2018 ⁽³⁾	06/30/2021	COMMON SHARES	24,720 ⁽⁵⁾		24,720 ⁽⁵⁾	D	
OPTION TO PURCHASE COMMON SHARES	\$3.57							07/03/2018 ⁽³⁾	06/30/2020	COMMON SHARES	24,720 ⁽⁵⁾		24,720 ⁽⁵⁾	D	

Explanation of Responses:

- These options will vest and become exercisable on June 30, 2020, provided, that Neal C. Bradsher remains a member of the issuer's board of directors on that date.
- The options were granted to Neal Bradsher by the issuer on July 1, 2019 as director compensation pursuant to resolutions from the minutes of the issuer's board of directors meeting on January 24, 2018.
- These options are currently exercisable.
- On November 28, 2018, the issuer distributed to its shareholders approximately 12.7 million shares of common stock of AgeX Therapeutics, Inc. ("AgeX") in the ratio of one share of AgeX common stock for every 10 common shares of the issuer owned by its shareholders (the "AgeX Distribution"). Pursuant to the AgeX Distribution, the issuer adjusted the amount of options held by its directors. In particular, the 40,000 options expiring on June 30, 2023 that were previously granted to Neal C. Bradsher were increased to 49,440 to reflect the AgeX Distribution.
- Pursuant to the AgeX Distribution, (i) the 20,000 options expiring on June 30, 2022 that were previously granted to Neal C. Bradsher were increased to 24,720, (ii) the 20,000 options expiring on June 30, 2021 that were previously granted to Neal C. Bradsher were increased to 24,720, and (iii) the 20,000 options expiring on June 30, 2020 that were previously granted to Neal C. Bradsher were increased to 24,720.

/s/ Neal C. Bradsher 07/03/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.